Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.

Trends in pharmacological sciences - 1 Aug 2025

Minor Allegra C, Couser Evan, Eichner Lillian J

Abstract excerpt

Despite the development of new classes of therapeutics in oncology, patients with tumors harboring mutations in the tumor suppressor gene STK11/LKB1 continue to exhibit poor clinical response and therapeutic resistance. Recent advances in the understanding of LKB1-mutant tumor biology have illuminated how metabolism and the tumor microenvironment (TME) function as effectors of the aggressive nature of this tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to STK11 gene

Share to Mutation

Share to Neoplasms

Share to Protein Serine-Threonine Kinases

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 40701847
DOI: 10.1016/j.tips.2025.06.008
PMCID: PMC12372497

Genes

STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.PMID 40701847Read ↗

Targeting LKB1 in cancer - exposing and exploiting vulnerabilities.Semantic proximity Read ↗

Metabolic reprogramming of the tumor microenvironment to enhance immunotherapySemantic proximity Read ↗

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammationSemantic proximity Read ↗

LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases.Semantic proximity Read ↗

Genomic alterations and their correlation with metabolic-related genes in lung cancer.Semantic proximity Read ↗

The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progressionSemantic proximity Read ↗

Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.Semantic proximity Read ↗

LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancerSemantic proximity Read ↗

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.Semantic proximity Read ↗

Microenvironment-Driven Reprogramming in Colorectal Cancer Liver Metastasis: Metabolic, Phenotypic, and Immune Adaptation.Semantic proximity Read ↗

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read ↗

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivatedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.